Replies to post #2336 on Dendreon Corp fka DNDNQ

[Biowatch]

>The FDA said it would ask the panel whether a 3.9% stroke rate seen among Provenge patients - compared with a 2.6% rate among patients in the placebo groups - was a "potential safety signal" for Provenge."<

I was wondering what in particular might trigger a stroke in these patients, other than age.